Since treatment of HCC cells with class I PI3K inhibitors leads to the expansion of liver CSCs via activating SGK323, while PIK3C3 inhibitor could inhibit the expansion of liver CSCs via inactivating SGK3, we examined whether PIK3C3 inhibitor could abrogate the expansion of liver CSCs induced by PI3K inhibitor (ZSTK474). Here, SGK3 is linked to hepatocellular carcinoma.